ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2990

Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort

Anna-Maria Hoffmann-Vold1,2, Oyvind Midtvedt1, Torhild Garen3, May Brit Lund4, Arne Andreassen5 and Øyvind Molberg6, 1Rheumatology, Oslo University Hospital, Oslo, Norway, 2Institute of clinical medicine, University of Oslo, Oslo, Norway, 3Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 4Respiratory Diseases, Oslo University Hospital, Oslo, Norway, 5Cardiology, Oslo University Hospital, Oslo, Norway, 6Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, pulmonary complications and systemic sclerosis, Pulmonary Involvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:
In Systemic
Sclerosis (SSc), pulmonary arterial hypertension (PAH) is often diagnosed at an
advanced stage.
Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are typically elevated in
established SSc-PAH, but it is not known if the serum levels rise prior to PAH
diagnosis, and it is not known if NT-proBNP levels differ between PAH and
pulmonary hypertension secondary to interstitial lung disease (PH-ILD); which
is resistant to treatment. Here, we utilized serial serum samples from a large,
prospective and unselected SSc cohort, and approached these two questions by
testing NT-proBNP levels in sera
obtained before and after PAH or PH-ILD diagnoses.


<>Methods: The
study cohort included patients from the prospective, observational Oslo
University Hospital SSc cohort (n=298) who
met the 2013 ACR/EULAR
classification criteria

and had (A)
baseline and follow-up
serum samples available for NT-proBNP
analyses, (B) baseline and follow-up data on systolic pulmonary artery pressure (sPAP) by echocardiography (ECHO) and diffusion
capacity for carbon monoxide (DLCO), and (C) follow-up data on PAH and PH-ILD
diagnoses by right heart catheterization (RHC).


<>Results: The study cohort included 298 consecutive SSc patients
(243 female, 78 diffuse cutaneous SSc) aged
48 ± 15.4 years at disease onset. During an observation period of 11.5  ± 8.0 years 52/298 patients developed PH,
of those 32/52 were diagnosed with PAH, and 20/52 had PH-ILD. Serum levels of
NT-pro-BNP obtained at baseline (mean 1.4 years before PH diagnoses) did not
differ between cases with and without PH (Table 1). There was, however, a
difference in NT-proBNP levels between PH and non-PH cases in serum samples
obtained at follow-up, mean 2.6 years after the PH
diagnoses. Development of PH was positively associated with sPAP
values obtained at baseline, mean 1.6 years before PH diagnosis, and at
follow-up: Likewise, PH was also associated with DLCO at baseline and at
follow-up (Table 1). None of these parameters could significantly segregate PAH
from PH-ILD.


<>Conclusion: In this prospective SSc cohort we did not find any
difference in baseline NT-proBNP levels between PH and non PH cases; indicating
that NT-proBNP analyses are not useful for predicting PH development. In
contrast, we found that the values of sPAP and DLCO differed
between PH and non PH cases both at baseline and follow-up. None of the markers
tested could differentiate between PAH and PH-ILD. Hence, we are still missing
predictive biomarkers for the development of PAH.

Table 1: Associations
between PH and baseline and follow up characteristics

No PH

N=246

PH

N=52

p-value

NT-proBNP; mg/ml, SD

A.      Baseline

64.1 ± 325.9

116.1 ± 172.6

0.265

B.      Follow-up

155.8 ± 546.1

399.4 ± 666.3

0.018

sPAP by ECHO in mmHg, SD

A.      Baseline

22.9 ± 10.5

50.2 ± 30.8

<0.001

B.      Follow-up

26.6 ± 13.4

69.3 ± 25.2

<0.001

DLCO, % of value expected, SD

A.      Baseline

71.8 ± 20.0

51.3 ± 21.7

<0.001

B.      Follow-up

64.6 ± 19.0

37.9 ± 14.8

<0.001

 


Disclosure: A. M. Hoffmann-Vold, None; O. Midtvedt, None; T. Garen, None; M. B. Lund, None; A. Andreassen, None; Molberg, None.

To cite this abstract in AMA style:

Hoffmann-Vold AM, Midtvedt O, Garen T, Lund MB, Andreassen A, Molberg . Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/assessment-of-nt-pro-bnp-as-a-potential-marker-for-pulmonary-hypertension-in-systemic-sclerosis-data-from-a-large-prospective-and-unselected-patient-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-nt-pro-bnp-as-a-potential-marker-for-pulmonary-hypertension-in-systemic-sclerosis-data-from-a-large-prospective-and-unselected-patient-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology